

## Low- versus conventional-dose trimethoprim-sulfamethoxazole for non-HIV PCP

Tatsuya Nagai<sup>1</sup>, Hiroki Matsui<sup>2,3</sup>, Haruka Fujioka<sup>1</sup>, Yuya Homma<sup>1</sup>, Ayumu Otsuki<sup>1</sup>, Hiroyuki Ito<sup>1</sup>, Shinichiro Ohmura<sup>4</sup>, Toshiaki Miyamoto<sup>4</sup>, Daisuke Shichi<sup>5</sup>, Watari Tomohisa<sup>6</sup>, Yoshihito Otsuka<sup>6</sup>, Kei Nakashima\*<sup>1</sup>

<sup>1</sup>Department of Pulmonology, Kameda Medical Center, Chiba, Japan

<sup>2</sup>Department of Clinical Epidemiology and Health Economics, School of Public Health, the University of Tokyo, Japan

<sup>3</sup>Clinical Research Support Office, Kameda Medical Center, Chiba, Japan

<sup>4</sup>Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan

<sup>5</sup>Department of Infectious Diseases and Rheumatology, Seirei Mikatahara General Hospital, Hamamatsu, Japan

<sup>6</sup>Department of Laboratory Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan

\*Corresponding author: Kei Nakashima

Department of Pulmonology, Kameda Medical Center, 929 Higashi-cho, Kamogawa,

Chiba 296-8602, Japan

Tel: +81 4 7092 2211, Fax: +81 4 7092 1198

Email: [kei.7.nakashima@gmail.com](mailto:kei.7.nakashima@gmail.com)

### Take home message

Low-dose TMP-SMX treatment for non-HIV PCP showed no difference in mortality and fewer side effects compared with treatment with conventional doses. Therefore, it may be an effective

alternative, but further research is needed to confirm our results.

## Abstract

Trimethoprim-sulfamethoxazole (TMP-SMX) is an effective treatment for *Pneumocystis jirovecii* pneumonia (PCP); however, a high incidence of adverse events has been observed. Low-dose TMP-SMX is a potentially effective treatment with fewer adverse events; however, evidence is limited. We aimed to evaluate the efficacy and safety of low-dose TMP-SMX after adjusting for patient background characteristics.

In this multicentre retrospective cohort study, we included patients diagnosed with non-human immunodeficiency virus (HIV) PCP and treated with TMP-SMX between June 2006 and March 2021 at three institutions. The patients were classified into low- (TMP equivalent <12.5 mg/kg) and conventional-dose groups (TMP equivalent 12.5–20 mg/kg/day). The primary endpoint was 30-day mortality, and the secondary endpoints were 180-day mortality, adverse events of grade 3 or greater per the Common Terminology Criteria for Adverse Events Version 5.0, and initial treatment completion rates. The background characteristics were adjusted using the overlap weighting method with propensity scores.

Fifty-five patients in the low-dose and 81 in the conventional-dose groups were evaluated. There was no significant difference in 30-day mortality (7.6% vs. 14.9%,  $P = 0.215$ ) or 180-day mortality (18.1% vs. 24.0%,  $P = 0.416$ ) after adjusting for patient background characteristics. The incidence of adverse events, especially nausea and hyponatremia, was significantly lower in the low-dose group (27.3% vs. 58.6%,  $P = 0.001$ ). The initial treatment completion rates were 43.8% and 27.7% in the low-dose and conventional-dose groups, respectively.

Low-dose TMP-SMX did not alter survival but reduced the incidence of adverse events in patients with non-HIV PCP, compared with conventional-dose TMP-SMX.

**Keywords:** Immunocompromised patients; Low-dose trimethoprim-sulfamethoxazole;  
Non-human immunodeficiency virus-infected patients; Pneumocystis pneumonia; Treatment.

## Introduction

*Pneumocystis jirovecii* pneumonia (PCP) is a widely known opportunistic infection in immunocompromised patients [1, 2]. The occurrence of PCP in patients with acquired immune deficiency syndrome has been problematic worldwide since the 1980s; however, the frequency of PCP in this population has decreased significantly owing to early treatment for human immunodeficiency virus (HIV) in recent years [2, 3]. Nevertheless, the occurrence of PCP in non-HIV patients has increased owing to the use of immunosuppressive drugs, anticancer drugs, and the increasing number of patients undergoing organ transplantations [2, 4]. Furthermore, the mortality rate (30–60%) of non-HIV PCP is higher than that (10–20%) of HIV PCP owing to a strong inflammatory response to a smaller number of organisms, unlike milder immune reactions in HIV PCP [1, 2]. Therefore, it is crucial to improve the therapeutic management of PCP in non-HIV immunocompromised patients to improve their prognoses.

Prior reviews and guidelines indicate that the first-line therapy for patients with non-HIV PCP and HIV PCP is trimethoprim-sulfamethoxazole (TMP/SMX), and doses of 15–20 mg/kg/day TMP and 75–100 mg/kg/day SMX are recommended [1, 2, 5-8]. The efficacy of TMP/SMX as a standard therapy is clear; however, it is associated with a high incidence of adverse events, including drug rashes and gastrointestinal, liver, dose-dependent renal, and blood disorders, that make it difficult to continue treatment [9-11]. Therefore, studies on low-dose therapy (TMP 10–15 mg/kg/day or less) and step-down therapy with TMP/SMX have been conducted; these suggested comparable therapeutic effects and the reduction of the incidence of adverse effects compared with that in standard therapy [11-16]. However, the evidence is insufficient because there are only a small number of retrospective studies [11-15], and the patient background between the low-dose and conventional-dose groups was not adjusted to compare mortality rates and safety [16]. In a prior study, Hammarstrom et al. found no differences in respiratory function changes between the baseline and day 8 in low-dose and

conventional-dose TMP-SMX groups by employing an adjusted regression model for treating PCP patients with haematological malignancies [16]. However, this study did not evaluate 30-day mortality or adverse reactions after adjusting for potential confounders, and it was limited to patients with haematological malignancies as their underlying diseases.

Therefore, we aimed to evaluate the efficacy and safety of low-dose TMP/SMX compared with those of conventional-dose TMP/SMX in non-HIV PCP patients with various underlying diseases. We set 30-day mortality as the primary endpoint after adjusting for patient background in a multicentre cohort study.

## Methods

### *Study Design and Study Population*

This was a multicentre retrospective observational cohort study involving clinically diagnosed non-HIV PCP patients treated with TMP-SMX. We retrospectively enrolled non-HIV patients diagnosed with pneumocystis pneumonia between January 2006 and March 2021 at Kameda General Hospital, Seirei Hamamatsu Hospital, and Seirei Mikatahara Hospital (registry named RE-VISION-PCP: Registry to Provide New Evidence and Insights for the Management of Pneumocystis Pneumonia in Non-HIV-infected Patients). The diagnostic criteria for PCP were defined as follows [11, 17]: 1) clinical symptoms consistent with those of PCP (dyspnoea, cough, fever, hypoxemia), 2) chest X-ray or chest CT scans showing abnormal shadows (such as bilateral ground-glass opacities) consistent with PCP findings, 3) *Pneumocystis* detected in respiratory specimens such as sputum or bronchoalveolar lavage fluid through conventional staining (Grocott methenamine silver or Diff-Quick staining) or deoxyribonucleic acid testing (loop-mediated isothermal amplification or polymerase chain reaction), and 4) elevated  $\beta$ -D-glucan concentrations with an appropriate response to standard therapy for PCP. Serum  $\beta$ -D-glucan concentrations were measured using either the  $\beta$ -D-glucan

test kit (Wako Pure Chemical Industries, Osaka, Japan) or the FUNGITEC G test MKII (Nissui Pharmaceutical, Tokyo, Japan). Elevated  $\beta$ -D-glucan levels were defined as  $>5$  pg/mL ( $\beta$ -D-glucan test; Wako assay) or  $>20$  pg/mL (FUNGITEC G-test KM assay) [18, 19]. 1) Patients who did not receive any treatment, 2) Patients who were initially treated with regimens other than TMP/SMX, and 3) patients receiving  $>20$  mg/kg of TMP were excluded. The study protocol was reviewed and approved by the research ethics committees of Kameda General Hospital (#21-069), Seirei Hamamatsu Hospital (#3584), and Seirei Mikatahara Hospital (#21-58). This was a retrospective study, and the patient information was anonymized; therefore, written informed consent was not obtained.

#### *Definitions of the Low-Dose and Conventional-Dose TMP-SMX Treatment Groups*

Patients were divided into low- and conventional-dose TMP-SMX treatment groups according to the amount of TMP-SMX. The dosage of TMP-SMX was calculated by multiplying a correction factor according to creatinine clearance because dose adjustment and reduction according to the degree of renal dysfunction are necessary [13]. Creatinine clearance was calculated using the Cockcroft–Gault formula [20]. The specific correction coefficients were classified as 1 for CrCl  $> 50$  mL/min; 1.5 for CrCl 30–50 mL/min; 2.0 for CrCl 15–30 mL/min; and 3.0 for CrCl  $< 15$  mL/min or haemodialysis use [13]. The low-dose group was defined as patients treated with an initial dose of TMP  $<12.5$  mg/kg/day, while the conventional-dose group was defined as patients treated with an initial dose of TMP of 12.5–20 mg/kg/day. Previous studies have defined low-dose TMP-SMX as TMP at 10–15 mg/kg/day [11-16]. Additionally, a threshold of 13.85 mg/kg/day has been reported as the point of severe adverse reactions in the corresponding area under the receiver operating characteristic curves used to distinguish patients with severe adverse reactions [14]. Thus, we established a TMP dose of 12.5 mg/kg/day, which represents the median dose of 10–15 mg/kg/day, as the cut-off

point for low-dose treatment.

### *Outcomes*

The primary endpoint was 30-day mortality from the start of treatment. The secondary endpoints were mortality at 180 days from the beginning of treatment, the incidence of each adverse event, and the completion rate of initial treatment.

### *Data Collection*

Data on patient characteristics including age, sex, weight, underlying diseases, laboratory results (platelet count; haemoglobin, serum albumin, lactate dehydrogenase, serum sodium, serum potassium, and creatinine levels; creatinine clearance), state of consciousness, presence of hypotension, respiratory status (including no oxygen support, oxygen support, and mechanical ventilation with options like high-flow nasal cannula, non-invasive positive-pressure ventilation, and intubation), dose of TMP-SMX, use of adjunctive glucocorticoid therapy (steroid pulse therapy is defined as the initial administration of methylprednisolone at 500mg-1000mg/day, while a mild to moderate doses is defined as a steroid dose less than that of steroid pulse therapy), 30- and 180-day mortality rates, the occurrence of grade 3 or higher adverse events, and the discontinuation of the initial regimen were collected retrospectively from medical records. Adverse drug reactions were evaluated according to the Common Terminology Criteria for Adverse Events Version 5.0 [21]; this included grade 3 or higher skin rashes, nausea, decreases in white blood cell counts, anaemia, thrombocytopenia, increases in plasma aspartate aminotransferase (AST) levels, increases in plasma alanine aminotransferase (ALT) levels, hyponatremia, and hyperkalaemia.

### *Statistical Analyses*



Because of the retrospective and observational nature of this study, we conducted it using the available number of cases and did not perform any sample size calculations. We obtained descriptive statistics of the baseline characteristics and outcomes between the low- and conventional-dose groups. No missing values were observed in the variables included in the analysis. Continuous variables are expressed as mean  $\pm$  standard deviation, and categorical variables are expressed as numbers (%). The balance between the groups for each baseline characteristic was assessed using the standardized mean difference (SMD). Generally, groups are considered balanced when the SMD is less than 0.1 [22]. Outcomes between the groups were tested using *t*-tests for continuous and the  $\chi$ -square test for categorical variables. The significance level was set to 0.05. We used overlap weighting with a propensity score to obtain risk-adjusted cohorts [23]. Propensity scores were calculated using logistic regression with the exposure as the dependent variable and age, sex, history of malignancies, serum albumin levels, lactate dehydrogenase levels and respiratory status as the explanatory variables. These explanatory variables are prognostic factors for pneumocystis pneumonia [5, 24]. We described the patient demographics of the risk-adjusted cohorts similarly to those of the unadjusted cohort. We evaluated the balance between the groups using the SMD. Outcomes were also compared between the groups similarly to those of the unadjusted cohort.

## Results

A flowchart of the patient selection process is shown in Figure 1. In total, 164 non-HIV immunocompromised patients diagnosed with PCP were included. Among them, five patients who did not receive any treatment, 16 who received initial treatment other than TMP-SMX, and seven who received more than 20 mg/kg of TMP were excluded. Finally, 81 patients were included in the conventional-dose group and 55 in the low-dose group.

The demographic and clinical unadjusted and adjusted characteristics of eligible

patients stratified by the TMP-SMX dose are summarized in Table 1. Patient characteristics with SMDs above 10% were unbalanced, while those with SMDs below 10% were balanced. Sex, median weight, and the presence of malignancies or connective tissue disease were unbalanced. Among the haematology findings, the platelet count was balanced, while the other parameters were unbalanced. Hypotension (systolic blood pressure <90 mmHg) and respiratory status were unbalanced, whereas glucocorticoid non-use was balanced. Adjusted patient characteristics included age, sex, underlying diseases, serum albumin levels, serum lactate dehydrogenase levels, and respiratory status, with SMDs less than 10%.

Data on the primary and secondary endpoints for eligible patients stratified by the TMP-SMX dose are presented in Table 2. The unadjusted 30-day mortality rate was 7.3% in the low-dose group and 17.3% in the conventional-dose group. The 180-day survival rate was 18.2% in the low-dose group and 28.4% in the conventional-dose group; however, the difference was not significant. Similarly, the adjusted mortality rates were not significantly different (7.6% in the low-dose group and 14.9% in the conventional-dose group for 30-day mortality, and 18.1% in the low-dose group and 24.0% in the conventional-dose group for 180-day mortality). The unadjusted total adverse reaction rate was significantly lower in the low-dose group (29.1%) than in the conventional-dose group (56.8%). The adjusted total adverse reaction rate was also significantly lower in the low-dose group (27.3%) than in the conventional-dose group (58.6%). In the unadjusted population, the incidence of nausea grade 3 or higher was 0% in the low-dose group and 9.9% in the conventional-dose group and that of hyponatremia was 7.3% in the low-dose group and 28.4% in the conventional-dose group; the incidence of these adverse reactions was significantly lower in the low-dose group than in the conventional-dose group. The incidence of nausea and hyponatremia was lower in the low-dose group than in the conventional-dose group in the adjusted population. In contrast, there were no significant differences in the incidence of skin rashes, leukopenia, anaemia,

thrombocytopenia, ALT elevation, or hyperkalaemia. The unadjusted initial treatment completion rate was 43.6% in the low-dose group and 28.4% in the conventional-dose group, while the adjusted initial treatment completion rate was 43.8% in the low-dose group and 27.7% in the conventional-dose group.

## Discussion

This multicentre retrospective observational study evaluated the treatment outcomes of low-dose versus conventional-dose TMP-SMX in patients with non-HIV PCP after adjusting for patient demographics and clinical characteristics. There were no significant differences in the 30- and 180-day survival rates between the low- and conventional-dose groups. However, the rate of total adverse events of grade  $\geq 3$  was significantly lower in the low-dose group than in the conventional-dose group. To the best of our knowledge, this is the first and largest multicentre study to evaluate the mortality rate and safety of low-dose TMP-SMX for non-HIV PCP after adjusting for patient characteristics. We believe that our findings offer additional evidence supporting the effectiveness of low-dose TMP-SMX treatment for the management of non-HIV PCP.

Recent guidelines set the conventional dose of TMP and SMX at 15–20 mg/kg and 75–100 mg/kg, respectively [5-7]. However, because of concerns about adverse events and tolerability of the conventional dose and because the current recommended dose for non-HIV PCP is based on small observational studies conducted in the 1970s and 1980s [25-27], several studies have recently examined the efficacy of low-dose or step-down treatment with TMP-SMX. In 2020, Butler-Laporte et al. published a systematic review and meta-analysis of low-dose TMP-SMX for PCP treatment; the treatment of PCP with trimethoprim at doses of 15 mg/kg/day or less had similar mortality rates and significantly fewer severe adverse events attributable to the treatment than did treatment with conventional doses [15]. Among the

included studies, three [11, 13, 14] were retrospective studies of conventional and low doses, with mortality and adverse effects as outcomes. In one study (where a low dose was defined as  $\text{TMP} < 10 \text{ mg/kg/day}$ ), no comparisons were made, and it was purely descriptive [11]. Two of the studies comparing mortality and adverse events between low- and conventional-dose TMP-SMX for PCP showed no statistically significant difference in mortality [13, 14], although patient background was not adjusted for in either study. Recently, Hammarstrom et al. compared low-dose (TMP equivalent 7.5–15 mg/kg/day) and conventional-dose TMP-SMX (TMP equivalent 15–20 mg/kg/day) in patients with haematological malignancies [16]. They evaluated the change in respiratory function measured as the difference in  $\text{PaO}_2/\text{FiO}_2$  ratio between the baseline and day 8 as a primary endpoint. There were no significant differences in the primary endpoint between the two groups, either before or after controlling for potential confounders in an adjusted regression model [16]. The target population for this study was restricted to patients with haematological malignancies, and only three covariates (age, Eastern Cooperative Oncology Group performance status, and P/F ratio at baseline) were utilized for adjustment. In contrast, our study evaluated the mortality and safety of low-dose TMP-SMX ( $\text{TMP} < 12.5 \text{ mg/kg/day}$ ) in non-HIV PCP patients with a wide range of underlying diseases, including collagen disease, solid tumours, and haematological malignancies. We adjusted for patient background by considering six prognostic factors that influence mortality in non-HIV PCP patients: age, sex, history of malignancies, serum albumin levels, serum lactate dehydrogenase levels and respiratory status [5, 24].

In the present study, the 30- and 180-day mortality rates of the low-dose group were 7.6 and 18.1%, respectively, after adjusting for patient background; they were not significantly different from those of the conventional-dose group. There are several possible explanations for this result. First, it is possible to obtain sufficient minimum inhibitory concentration (MIC) for *Pneumocystis jirovecii* in blood and tissues, even at low doses. To ensure adequate

therapeutic efficacy of TMP-SMX, a dose above the MIC must be ensured [28]; however, continuous *in vitro* cultures of *Pneumocystis* for testing its susceptibility to antimicrobial agents have not been performed [29]. Therefore, the required dosage for PCP treatment was determined based on the results of clinical studies [11]. One tablet of TMP-SMX (80 mg of TMP and 400 mg of SMX; equivalent to 1.3 mg/kg/day TMP and 6.7 mg/kg/day SMX for a 60 kg body) once daily is recommended and is sufficient for preventing the onset of PCP [30]. Generally, the dose of antimicrobial agents required to prevent disease onset has a concentration above the MIC in many infections [31]. Therefore, lower doses of TMP-SMX than conventional-dose (TMP equivalent 15-20 mg/kg/day) could have a sufficient therapeutic effect [11]. Second, there were fewer adverse events in the low-dose group than in the conventional-dose group in the present study. TMP-SMX is associated with a dose-dependent incidence of adverse events, such as skin rashes, gastrointestinal disturbances, myelosuppression, renal disturbances, hepatic disturbances, and electrolyte disturbances [32]; 57% of patients with HIV PCP change from this treatment owing to serious adverse events [33]. In the current study, after adjusting for patient background, there were significantly fewer adverse events in the low-dose (27.3%) than those in the conventional-dose groups (58.6%), with nausea and hyponatremia being significantly less common. This reduction in the incidence of adverse events could have facilitated the management of PCP. Therefore, low-dose TMP-SMX may be an effective treatment for non-HIV PCP and should be considered a treatment option.

The definition of low-dose TMP-SMX treatment remains unclear, with some studies defining it as TMP < 10 mg/kg/day [11, 14] and others as TMP < 15 mg/kg/day [13, 16]. In a study by Ohmura et al., the optimal dosage of TMP/SMX treatment to minimize severe adverse events was investigated using receiver operating characteristic curves, reporting a threshold TMP dose of 13.8 mg/kg/day [14]. Consequently, in our study, we referred to this value and

defined the low dose as  $\text{TMP} < 12.5 \text{ mg/kg/day}$ . Further investigation is warranted to determine the optimal threshold for low-dose TMP-SMX combination therapy.

Our study findings suggest that low-dose TMP-SMX treatment may be a viable option for clinicians. However, future research, including large-scale observational studies and randomized controlled trials, is needed to confirm the efficacy of low-dose TMP-SMX.

This study has some limitations. First, this was a retrospective observational study. Therefore, there could be a bias in patient selection and treatment choice. We adjusted as much as possible for the mortality risk factors that could affect patient outcomes; however, there could have been unrecognized confounding factors. Second, the blood levels of TMP-SMX were not measured; therefore, it is unclear whether there is a true correlation between actual blood levels and treatment response or adverse events. Maintaining the blood levels of TMP-SMX in the appropriate range is important to ensure therapeutic efficacy and reduce the incidence of adverse events; however, actual blood levels are dependent on renal function, liver function, and body size [34]. Third, only a few patients with severe respiratory failure, such as those on ventilators, were included, and the efficacy of TMP-SMX in such patients with severe respiratory failure is unknown.

## **Conclusions**

Low-dose TMP-SMX treatment for non-HIV PCP was associated with no difference in mortality and few side effects compared with those of conventional-dose treatment.

Low-dose TMP-SMX may be an effective treatment option for non-HIV-associated PCP. The retrospective observational nature of the study and the small number of seriously ill patients warrant further investigations in larger prospective randomized controlled trials or cohort studies.

*Conflicts of interest:* None.

*Acknowledgements:* We thank the Department of Medical Oncology, Haematology/Oncology, and Rheumatology doctors at Kameda Medical Center for providing the case data.

*Funding:* None.

*CRedit statement:*

Conceptualization: T.N., H.M., S.O., K.N. Data curation: T.N., H.M., S.O., K.N. Formal analysis: H.M. Investigation: T.N., H.F., Y.H., S.O., D.S. Methodology: T.N., H.M., S.O., K.N. Project administration: T.N., S.O., K.N. Resources: T.N., H.F., Y.H., A.O., H.I., S.O., T.M., D.S., W.T., Y.O., K.N. Software: H.M. Supervision: K.N. Validation: H.M., K.N. Visualization: T.N., H.M., K.N. Writing - original draft: T.N. Writing - review & editing: T.N., H.M., H.F., Y.H., A.O., H.I., S.O., T.M., D.S., W.T., Y.O., K.N.

**Table 1** Baseline clinical characteristics of the study population (when administered with TMP/SMX)

	Un-adjusted patient cohort			Adjusted patient cohort		
	Low dose <i>n</i> = 55	Conventional dose <i>n</i> = 81	SMD	Low dose <i>n</i> = 30.9	Conventional dose <i>n</i> = 30.9	SMD
Age (years)	70.95 (±9.95)	70.59 (±11.35)	0.033	70.47 (±9.84)	70.47 (±11.20)	<0.001
Female	27 (49.1)	48 (59.3)	0.205	16.8 (54.3)	16.8 (54.3)	<0.001
Weight (kg)	57.69 (±11.61)	49.14 (±9.61)	0.803	57.51 (±11.51)	49.42 (±9.83)	0.755
Underlying diseases						
Malignancies*	10 (18.2)	20 (24.7)	0.159	6.7 (21.6)	6.7 (21.6)	<0.001
Haematological malignancies	3 (5.5)	10 (12.3)	0.244	2.3 (7.3)	3.4 (10.9)	0.123
Solid tumours	8 (14.5)	10 (12.3)	0.065	5.2 (16.8)	3.3 (10.8)	0.175
Connective tissue disease	45 (81.8)	54 (66.7)	0.352	24.4 (79.0)	21.1 (68.3)	0.244
Blood test findings						
Haemoglobin (g/dL)	12.05 (±2.07)	11.15 (±1.95)	0.450	11.91 (±2.03)	11.28 (±2.00)	0.309
Platelet count (×10 <sup>9</sup> /μL)	22.31 (±9.46)	22.14 (±11.1)	0.016	22.50 (±9.78)	22.19 (±10.98)	0.030
Albumin (g/dL)	3.02 (±0.64)	2.91 (±0.66)	0.165	2.97 (±0.66)	2.97 (±0.66)	<0.001
Lactate dehydrogenase (IU/L)	380.40 (±129.10)	413.21 (±171.33)	0.216	390.91 (±135.68)	390.91 (±151.63)	<0.001
Serum sodium (mEq/L)	138.55 (±4.50)	136.68 (±4.02)	0.437	138.74 (±4.80)	136.72 (±3.99)	0.457
Serum potassium (mEq/L)	4.11 (±0.48)	4.20 (±0.51)	0.177	4.08 (±0.51)	4.22 (±0.51)	0.288
Creatinine (mg/dL)	0.82 (±0.43)	1.06 (±1.29)	0.254	0.79 (±0.40)	1.11 (±1.34)	0.322
Creatinine clearance (mL/min)	71.28 (±26.80)	56.71 (±26.16)	0.550	72.94 (±26.91)	55.85 (±26.01)	0.646
Disturbed consciousness	0 (0.0)	2 (2.5)	0.225	0 (0.0)	0.9 (2.9)	0.245



Hypotension (systolic pressure < 90 mmHg)	0 (0.0)	3 (3.7)	0.277	0 (0.0)	1.1 (3.5)	0.271
Respiratory status			0.230			<0.001
Without oxygen	28 (50.9)	42 (51.9)		15.8 (51.0)	15.8 (51.0)	
Administration of oxygen	27 (49.1)	37 (45.7)		15.2 (49.0)	15.2 (49.0)	
1–4 L/min	17 (30.9)	23 (28.4)		9.2 (29.7)	9.9 (32.0)	
5–10 L/min	7 (12.7)	4 (4.9)		4.6 (14.7)	1.5 (4.9)	
11–15 L/min	3 (5.5)	10 (12.3)		1.4 (4.6)	3.8 (12.2)	
Mechanical ventilation	0 (0.0)	2 (2.5)		0 (0.0)	0 (0.0)	
high-flow nasal cannula	0 (0.0)	1 (1.23)		0 (0.0)	0 (0.0)	
non-invasive positive-pressure ventilation	0 (0.0)	1 (1.23)		0 (0.0)	0 (0.0)	
Intubation with mechanical ventilation	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Dose of TMP administration (mg/kg/day)	8.71 (±2.50)	17.78 (±4.80)	2.368	8.69 (±2.49)	17.44 (±4.56)	2.382
Adjunctive glucocorticoid therapy						
None	6 (10.9)	11 (13.6)	0.082	3.4 (10.8)	4.6 (14.8)	0.119
Yes (mild to moderate doses)	31 (56.4)	39 (48.1)	0.165	16.8 (54.3)	14.6 (47.1)	0.143
Yes (steroid pulse therapy)	18 (32.7)	31 (38.3)	0.116	10.8 (34.9)	11.8 (38.1)	0.066

Continuous variables are expressed as mean ± standard deviation, and categorical variables are expressed as numbers (%).

\*One patient had both solid cancer and hematologic malignancy concurrently.

SMD: standardized mean difference, TMP-SMX: trimethoprim-sulfamethoxazole

**Table 2** Outcome data

	Unadjusted patient cohort			Adjusted patient cohort		
	Low dose <i>n</i> = 55	Conventional dose <i>n</i> = 81	<i>P</i>	Low dose <i>n</i> = 30.9	Conventional dose <i>n</i> = 30.9	<i>P</i>
Primary endpoints						
30-day mortality	4 (7.3)	14 (17.3)	0.152	2.4 (7.6)	4.6 (14.9)	0.215
Secondary endpoints						
180-day mortality	10 (18.2)	23 (28.4)	0.246	5.6 (18.1)	7.4 (24.0)	0.416
Occurrence of grade 3 or higher adverse events						
Total	16 (29.1)	46 (56.8)	0.003	8.4 (27.3)	18.1 (58.6)	0.001
Skin rashes	8 (14.5)	14 (17.3)	0.851	4.2 (13.7)	5.7 (18.4)	0.478
Nausea	0 (0.0)	8 (9.9)	0.042	0 (0.0)	3.4 (11.1)	0.004
Leukopenia	0 (0.0)	1 (1.2)	1.000	0 (0.0)	0.4 (1.2)	0.319
Anaemia	0 (0.0)	2 (2.5)	0.654	0 (0.0)	0.8 (2.6)	0.159
Thrombocytopenia	2 (3.6)	2 (2.5)	1.000	1.1 (3.6)	0.8 (2.5)	0.733
Increased ALT levels	2 (3.6)	3 (3.7)	1.000	1.0 (3.2)	1.3 (4.2)	0.763
Increased hyponatremia	4 (7.3)	23 (28.4)	0.005	1.9 (6.2)	9.1 (29.5)	0.001
Increased hyperkalaemia	3 (5.5)	12 (14.8)	0.152	1.6 (5.2)	4.8 (15.4)	0.068
Continuity of initial regimen			0.137			0.123
Completion of initial treatment	24 (43.6)	23 (28.4)		13.5 (43.8)	8.6 (27.7)	
Completion of treatment by reducing dosage	2 (3.6)	6 (7.4)		1.0 (3.1)	2.4 (7.6)	
Dosing interruption due to adverse events	21 (38.2)	39 (48.1)		11.5 (37.1)	15.7 (50.7)	

Termination of treatment due to death	3 (5.5)	10 (12.3)	1.9 (6.0)	3.2 (10.3)
Others	5 (9.1)	3 (3.7)	3.1 (10.0)	1.1 (3.6)

---

Categorical variables are expressed as numbers (%).  
ALT: alanine aminotransferase

## References

1. Thomas CF, Jr., Limper AH. Pneumocystis pneumonia. *The New England journal of medicine* 2004; 350(24): 2487-2498.
2. Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. *J Infect Chemother* 2012; 18(6): 793-806.
3. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, Huang L, Beard CB, Kaplan JE. Current epidemiology of Pneumocystis pneumonia. *Emerging infectious diseases* 2004; 10(10): 1713-1720.
4. Maini R, Henderson KL, Sheridan EA, Lamagni T, Nichols G, Delpech V, Phin N. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. *Emerging infectious diseases* 2013; 19(3): 386-392.
5. Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P, the European Conference on Infections in Leukemia ajvoTEGfB, Marrow Transplantation TEOfR, Treatment of Cancer tIIHS, The European L. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. *J Antimicrob Chemother* 2016; 71(9): 2405-2413.
6. Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, Davies SF, Dismukes WE, Hage CA, Marr KA, Mody CH, Perfect JR, Stevens DA. An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients. *American journal of respiratory and critical care medicine* 2011; 183(1): 96-128.
7. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Names of contributors are listed in Appendix C. Available at: <https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf> Accessed 16 October 2022.
8. Weyant RB, Kabbani D, Doucette K, Lau C, Cervera C. Pneumocystis jirovecii: a review

- with a focus on prevention and treatment. *Expert Opin Pharmacother* 2021; 22(12): 1579-1592.
9. Lee K-Y, Huang C-H, Tang H-J, Yang C-J, Ko W-C, Chen Y-H, Lee Y-C, Hung C-C. Acute psychosis related to use of trimethoprim/sulfamethoxazole in the treatment of HIV-infected patients with *Pneumocystis jirovecii* pneumonia: a multicentre, retrospective study. *Journal of Antimicrobial Chemotherapy* 2012; 67(11): 2749-2754.
  10. Chang HM, Tsai HC, Lee SS, Kunin C, Lin PC, Wann SR, Chen YS. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS. *J Chin Med Assoc* 2016; 79(6): 314-319.
  11. Nakashima K, Aoshima M, Nakashita T, Hara M, Otsuki A, Noma S, Misawa M, Otsuka Y, Motojima S. Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study. *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi* 2018; 51(6): 810-820.
  12. Creemers-Schild D, Kroon FP, Kuijper EJ, de Boer MG. Treatment of *Pneumocystis pneumonia* with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study. *Infection* 2016; 44(3): 291-299.
  13. Kosaka M, Ushiki A, Ikuyama Y, Hirai K, Matsuo A, Hachiya T, Hanaoka M. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of *Pneumocystis Pneumonia* in Patients without HIV Infection. *Antimicrob Agents Chemother* 2017; 61(12).
  14. Ohmura SI, Naniwa T, Tamechika SY, Miyamoto T, Shichi D, Kazawa N, Iwagaitu S, Maeda S, Wada JI, Niimi A. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for *Pneumocystis jirovecii* pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study. *J Infect Chemother* 2019; 25(4): 253-261.
  15. Butler-Laporte G, Smyth E, Amar-Zifkin A, Cheng MP, McDonald EG, Lee TC. Low-Dose TMP-SMX in the Treatment of *Pneumocystis jirovecii* Pneumonia: A Systematic Review and Meta-analysis. *Open Forum Infect Dis* 2020; 7(5): ofaa112.

16. Hammarstrom H, Krifors A, Athlin S, Friman V, Golestani K, Hallgren A, Otto G, Oweling S, Pauksens K, Kinch A, Blennow O. Treatment with reduced dose trimethoprim-sulfamethoxazole is effective in mild to moderate *Pneumocystis jirovecii* pneumonia in patients with hematologic malignancies. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2022.
17. Harigai M, Koike R, Miyasaka N. *Pneumocystis* Pneumonia Associated with Infliximab in Japan. *New England Journal of Medicine* 2007; 357(18): 1874-1876.
18. Del Corpo O, Butler-Laporte G, Sheppard DC, Cheng MP, McDonald EG, Lee TC. Diagnostic accuracy of serum (1-3)-beta-D-glucan for *Pneumocystis jirovecii* pneumonia: a systematic review and meta-analysis. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2020; 26(9): 1137-1143.
19. Taniguchi J, Nakashima K, Matsui H, Watari T, Otsuki A, Ito H, Otsuka Y. Low cut-off value of serum (1,3)-beta-D-glucan for the diagnosis of *Pneumocystis* pneumonia in non-HIV patients: a retrospective cohort study. *BMC Infect Dis* 2021; 21(1): 1200.
20. D W Cockcroft MHG. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 11(16): 31-41.
21. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
22. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med* 2009; 28(25): 3083-3107.
23. Thomas LE, Li F, Pencina MJ. Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial. *Jama* 2020; 323(23): 2417-2418.
24. Liu Y, Su L, Jiang SJ, Qu H. Risk factors for mortality from *pneumocystis carinii* pneumonia (PCP) in non-HIV patients: a meta-analysis. *Oncotarget* 2017; 8(35): 59729-59739.
25. Hughes WT, McNabb PC, Makres TD, Feldman S. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of *Pneumocystis carinii* pneumonitis. *Antimicrobial agents and chemotherapy* 1974; 5(3): 289-293.

26. Hughes WT, Feldman S, Sanyal SK. Treatment of *Pneumocystis carinii* pneumonitis with trimethoprim-sulfamethoxazole. *Can Med Assoc J* 1975; 112(13 Spec No): 47-50.
27. D J Winston WKL, R P Gale, L S Young. Trimethoprim-sulfamethoxazole for the treatment of *Pneumocystis carinii* pneumonia. *Annals of internal medicine* 1980.
28. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. *Antimicrobial agents and chemotherapy* 2012; 56(6): 2795-2805.
29. Rodriguez M, Fishman JA. Prevention of infection due to *Pneumocystis* spp. in human immunodeficiency virus-negative immunocompromised patients. *Clin Microbiol Rev* 2004; 17(4): 770-782, table of contents.
30. Stern A GH, Paul M, Vidal L, Leibovici L. Prophylaxis for *Pneumocystis* pneumonia (PCP) in non-HIV immunocompromised patients (Review). *Cochrane Database of Systematic Reviews* 2014.
31. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A, Gruppo Italiano Malattie Ematologiche dell'Adulto Infection P. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. *The New England journal of medicine* 2005; 353(10): 977-987.
32. Haseeb A, Abourehab MAS, Almalki WA, Almontashri AM, Bajawi SA, Aljoaid AM, Alsahabi BM, Algethamy M, AlQarni A, Iqbal MS, Mutlaq A, Alghamdi S, Elrggal ME, Saleem Z, Radwan RM, Mahrous AJ, Faidah HS. Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in *Pneumocystis jirovecii* Pneumonia (PCP) Management: A Systematic Review. *Int J Environ Res Public Health* 2022; 19(5).
33. Medina I, Mills J, Leoung G, Hopewell PC, Lee B, Modin G, Benowitz N, Wofsy CB. Oral therapy for *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. *The New England journal of medicine* 1990; 323(12): 776-782.



34. Brown GR. Cotrimoxazole - optimal dosing in the critically ill. *Ann Intensive Care* 2014; 4:  
13.

### **Figure caption**

#### **Figure 1.** Patient selection flowchart

HIV, human immunodeficiency virus; TMP-SMX, trimethoprim-sulfamethoxazole; PCP, *Pneumocystis jirovecii* pneumonia

Non-HIV PCP patients  
between January 2006 and March 2021  
164 patients

28 patients were excluded:  
5 patients who did not receive any treatment  
16 patients who received initial treatment other than TMP-SMX  
7 patients who received >20 mg/kg TMP

Non-HIV PCP patients treated with TMP-SMX  
136 patients

Treatment with low-dose TMP-SMX  
55 patients

Treatment with conventional-dose TMP-SMX  
81 patients